Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Globus Medical, Inc. Class A Common Stock (NY: GMED )

83.93 -0.20 (-0.24%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
$100 Invested In Globus Medical 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Investors should take note of NYSE:GMED, a growth stock that remains attractively priced.
Based on Fundamental Analysis it can be said that NYSE:GMED is a growth stock which is not overvalued. 
Via Chartmill
Analyst Expectations For Globus Medical's Future
Via Benzinga
Top 2 Health Care Stocks That May Crash In February
Via Benzinga
Why NYSE:GMED is Poised for High Growth.
A fundamental and technical analysis of (NYSE:GMED): Exploring GLOBUS MEDICAL INC - A (NYSE:GMED)'s high growth characteristics. 
Via Chartmill
Stryker Had A Good Year Last Year; Here's How It's Looking For 2025
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74. 
Via Investor's Business Daily
Inspire Medical's Sleep Innovations Driving Big Gains
Inspire Medical, which makes innovative apnea relief devices, hit a key performance benchmark as its Relative Strength Rating jumped to 81. 
Via Investor's Business Daily
Price Over Earnings Overview: Globus Medical
Via Benzinga
Why GLOBUS MEDICAL INC - A (NYSE:GMED) qualifies as a high growth stock.
Delving into GLOBUS MEDICAL INC - A (NYSE:GMED)'s high Growth Prospects. 
Via Chartmill
16 Analysts Have This To Say About Globus Medical
Via Benzinga
Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices
Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
Inari Medical Stock Gets RS Rating Upgrade
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72. 
Via Investor's Business Daily
Should you consider GLOBUS MEDICAL INC - A (NYSE:GMED) for high growth investing?
Unlocking the high Growth Potential of GLOBUS MEDICAL INC - A (NYSE:GMED). 
Via Chartmill
Novocure Stock Earns 96 RS Rating
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73. 
Via Investor's Business Daily
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
Evaluating Globus Medical: Insights From 11 Financial Analysts
Via Benzinga
What 7 Analyst Ratings Have To Say About Globus Medical
Via Benzinga
The Analyst Verdict: Globus Medical In The Eyes Of 7 Experts
Via Benzinga
Despite its growth, NYSE:GMED remains within the realm of affordability.
GLOBUS MEDICAL INC - A (NYSE:GMED) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
CVS Health, Johnson Controls And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Globus Medical (GMED) Q3 2024 Earnings Call Transcript
GMED earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NYSE:GMED is showing good growth, while it is not too expensive.
In the world of growth stocks, NYSE:GMED shines as a value proposition. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Looking Into Globus Medical's Recent Short Interest
Via Benzinga
A Glimpse Into The Expert Outlook On Globus Medical Through 8 Analysts
Via Benzinga
While growth is established for NYSE:GMED, the stock's valuation remains reasonable.
While growth is established for NYSE:GMED, the stock's valuation remains reasonable. 
Via Chartmill
Investors should take note of NYSE:GMED, a growth stock that remains attractively priced.
GLOBUS MEDICAL INC - A (NYSE:GMED) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
Looking Into Globus Medical's Recent Short Interest
Via Benzinga
What 8 Analyst Ratings Have To Say About Globus Medical
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.